Sanofi, RadioMedix, and Orano Med Announce Licensing Agreement for Next-Generation Radioligand Medicine Targeting Rare Cancers
As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet medical needs in cancer, and Orano Med, a French clinical-stage biotechnology company, […]
